Abstract
Rebleeding from peptic ulcers is a major unsolved problem in the management of acute upper gastrointestinal bleeding. Our goal was to review what is known and what remains to be learned about the effectiveness of antisecretory therapy for acute upper gastrointestinal bleeding. We reviewed the data regarding the effectiveness of endoscopic therapy, the prediction of those at increased risk for rebleeding, and the effectiveness of antisecretory drug therapy in preventing rebleeding with or without endoscopic hemostasis. Proton pump inhibitor therapy without endoscopic hemostasis is ineffective clinically for stopping bleeding or preventing rebleeding. Endoscopic hemostasis remains the cornerstone of therapy. The data are consistent with the notion that reliable maintenance of the intragastric pH at ≥6 after endoscopic hemostasis is associated with the lowest rebleeding rates. H2-receptor antagonists are ineffective for achieving this goal. Intermittent bolus and oral administration of proton pump inhibitors are equivalent and fail to achieve this goal, which can only be accomplished by bolus administration of a proton pump inhibitor (e.g., 80 mg) followed by a constant infusion (e.g., 8 mg/hr). Whether the combination of endoscopic hemostasis and pH control is equal or superior to selected second-look endoscopy is unknown. A treatment algorithm is suggested.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Laine L, Peterson W: Bleeding peptic ulcer. N Engl J Med 331:717–727, 1994
Saeed ZA, Winchester CB, Michaletz PA, Woods KL, Graham DY: A scoring system to predict rebleeding after endoscopic therapy of nonvariceal upper gastrointestinal hemorrhage, with a comparison of heat probe and ethanol injection. Am J Gastroenterol 88:1842–1849, 1993
Saeed ZA, Ramirez FC, Hepps KS, Cole RA, Graham DY: Prospective validation of the Baylor bleeding score for predicting the likelihood of rebleeding after endoscopic hemostasis of peptic ulcers. Gastrointest Endosc 41:561–565, 1995
Saeed ZA, Cole RA, Ramirez FC, Schneider FE, Hepps KS, Graham DY: Endoscopic retreatment after successful initial hemostasis prevents ulcer rebleeding: a prospective randomized trial. Endoscopy 28:288–294, 1996
Spiegel BM, Ofman JJ, Woods K, Vakil NB: Minimizing recurrent peptic ulcer hemorrhage after endoscopic hemostasis: the cost-effectiveness of competing strategies. Am J Gastroenterol 98:86–97, 2003
Patchett SE, Enright H, Afdhal N, O’Connell W, O’Donoghue DP: Clot lysis by gastric juice: an in vitro study. Gut 30:1704–1747, 1989
Green FW, Jr., Kaplan MM, Curtis LE, Levine PH: Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 74:38–43, 1978
Wilder–Smith CH, Merki HS. Tolerance during dosing with H2-receptor antagonists. An overview. Scand J Gastroenterol Suppl 193:14–19, 1992
Labenz J, Peitz U, Leusing C, Tillenburg B, Blum AL, Borsch G: Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study. Gut 40:36–41, 1997
Collins R, Langman M: Treatment with histamine H2 antagonists in acute upper gastrointestinal hemorrhage. Implications of randomized trials. N Engl J Med 313:660–666, 1985
Walt RP, Cottrell J, Mann SG, Freemantle NP, Langman MJ: Continuous intravenous famotidine for haemorrhage from peptic ulcer. Lancet 340:1058–1062, 1992
Merki HS, Wilder–Smith CH: Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 106:60–64, 1994
Netzer P, Gaia C, Sandoz M, et al.: Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol. 94:351–357, 1999
Kiilerich S, Rannem T, Elsborg L: Effect of intravenous infusion of omeprazole and ranitidine on twenty-four-hour intragastric pH in patients with a history of duodenal ulcer. Digestion 56:25–30, 1995
Kohler B, Benz C, Maier M, Knobloch M, Riemann JF: Gastric pH-monitoring in patients with acute ulcer bleeding under continuous intravenous therapy with omeprazole (omor ranitidine (ran). Gastroenterology 106:A109, 1994
Lin HJ, Lo WC, Lee FY, Perng CL, Tseng GY: A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med 158:54–58, 1998
Sachs G, Shin JM, Briving C, Wallmark B, Hersey: The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu Rev Pharmacol Toxicol 35:277–305, 1995
Hartmann M, Ehrlich A, Fuder H, et al.: Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. Aliment Pharmacol Ther 12:1027–1032, 1998
Brunner G, Luna P, Hartmann M, Wurst W: Optimizing the intragastric pH as a supportive therapy in upper GI bleeding. Yale J Biol Med 69:225–231, 1996
Khuroo MS, Yattoo GN, Javid G, et al.: A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 336:1054–1058, 1997
Daneshmend TK, Hawkey CJ, Langman MJ, Logan RF, Long RG, Walt RP: Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. BMJ 304:143–147, 1992
Hasselgren G, Lind T, Lundell L, et al.: Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study. Scand J Gastroenterol 32:328–333, 1997
Sung JY, Chan FK, Lau JWW, et al.: The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcer with nonbleeding visible vessels or adherent clots. A randomized comparson. Ann Intern Med 139:237–243, 2003
Hsieh YH, Lin HJ, Tseng GY, et al.: Poor responders to intravenous omeprazole in patients with peptic ulcer bleeding. Hepatogastroenterology 51:316–319, 2004
Javid G, Masoodi I, Zargar SA, et al.: Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer. Am J Med 111:280–284, 2001
Kaviani MJ, Hashemi MR, Kazemifar AR, et al.: Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther 17:211–216, 2003
Lau JY, Sung JJ, Lee KK, et al.: Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 343:310–316, 2000
Schaffalitzky de Muckadell OB, Havelund T, et al.: Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind placebo-controlled multicentre study. Scand J Gastroenterol 32:320–327, 1997
Schonekas H, Ahrens H, Pannewick U, et al.: Comparison of two doses of intravenous pantoprazole in peptic ulcer bleeding. Gastroenterology 116:A305, 1999
Udd M, Miettinen P, Palmu A, et al.: Regular-dose versus high-dose omeprazole in peptic ulcer bleeding: a prospective randomized double-blind study. Scand J Gastroenterol 36:1332–1338, 2001
Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares JM: Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther 15:917–926, 2001
Lanas A, Artal A, Blas JM, Arroyo MT, Lopez–Zaborras J, Sainz R: Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer. J Clin Gastroenterol 21:103–106, 1995
Villanueva C, Balanzo J, Torras X, et al.: Omeprazole versus ranitidine as adjunct therapy to endoscopic injection in actively bleeding ulcers: a prospective and randomized study. Endoscopy 27:308–312, 1995
Prassler R, Hendrich H, Barnert J, Richter G, Fleischmann R, Wienbeck M: [Do proton pump inhibitors after endoscopic control of acute ulcer hemorrhage have an advantage over H2 receptor antagonists?]. Z Gastroenterol 33:431–434, 1995
Cook DJ, Guyatt GH, Salena BJ, Laine LA: Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Gastroenterology 102:139–148, 1992
Sacks HS, Chalmers TC, Blum AL, Berrier J, Pagano D: Endoscopic hemostasis. An effective therapy for bleeding peptic ulcers. JAMA 264:494–499, 1990
Barkun A, Bardou M, Marshall JK: Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 139:843–857, 2003
Lau JY, Chung SC, Leung JW, Lo KK, Yung MY, Li AK: The evolution of stigmata of hemorrhage in bleeding peptic ulcers: a sequential endoscopic study. Endoscopy. 30:513–518, 1998
Oxner RB, Simmonds NJ, Gertner DJ, Nightingale JM, Burnham WR: Controlled trial of endoscopic injection treatment for bleeding from peptic ulcers with visible vessels. Lancet 339:966–968, 1992
Grosso C, Rossi A, Gambitta P, et al.: Non–bleeding visible vessel treatment: perendoscopic injection therapy versus omeprazole infusion. Scand J Gastroenterol 30:872–875, 1995
Jensen DM, Kovacs TO, Jutabha R, et al.: Randomized trial of medical or endoscopic therapy to prevent recurrent ulcer hemorrhage in patients with adherent clots. Gastroenterology 123:407–413, 2002
Bleau BL, Gostout CJ, Sherman KE, et al.: Recurrent bleeding from peptic ulcer associated with adherent clot: a randomized study comparing endoscopic treatment with medical therapy. Gastrointest Endosc 56:1–6, 2002
Henry DA, O’Connell DL: Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal haemorrhage. BMJ 298:1142–1146, 1989
Author information
Authors and Affiliations
Corresponding author
Additional information
Conflict of interest statement: In the last 3 years, Dr. Graham has received recent research support or honoraria for speaking engagements from AstraZeneca, Jannsen, Bayer HealthCare, TAP, Pharmacia, Meretek, Otsuka, Prometheus, and EISAI.
Rights and permissions
About this article
Cite this article
Julapalli, V.R., Graham, D.Y. Appropriate Use of Intravenous Proton Pump Inhibitors in the Management of Bleeding Peptic Ulcer. Dig Dis Sci 50, 1185–1193 (2005). https://doi.org/10.1007/s10620-005-2758-7
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10620-005-2758-7